BiotechTube

Oral Encochleated Amphotericin B (CAMB) + Fluconazole

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vulvovaginitis

Conditions

Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal

Trial Timeline

Nov 1, 2016 → May 1, 2017

NCT ID
NCT02971007

About Oral Encochleated Amphotericin B (CAMB) + Fluconazole

Oral Encochleated Amphotericin B (CAMB) + Fluconazole is a phase 2 stage product being developed by Matinas Biopharma for Vulvovaginitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02971007. Target conditions include Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02971007Phase 2Completed

Competing Products

3 competing products in Vulvovaginitis

See all competitors
ProductCompanyStageHype Score
Fluconazole + SCY-078ScynexisPhase 2
44
Ibrexafungerp + PlaceboScynexisPhase 3
69
Ibrexafungerp + PlaceboScynexisPhase 3
69

Other Products from Matinas Biopharma

Placebo + MAT9001 (omega-3 pentaenoic acid)Phase 3
69
MAT2203 + Amphotericin BPhase 3
69
Oral Encochleated Amphotericin B (CAMB)Phase 2
44
Amphotericin BPhase 2
44
Omega 3 pentaenoic acid + icosapent ethylPhase 2
44